<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444286</url>
  </required_header>
  <id_info>
    <org_study_id>Version No. 1.0</org_study_id>
    <nct_id>NCT02444286</nct_id>
  </id_info>
  <brief_title>The RESHAPE-HF1-FU Study</brief_title>
  <official_title>Observational Study of Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation - Follow Up of the Former Participants in the RESHAPE-HF Trial (Abbott Vascular).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Goettingen, sponsor of the study</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficiency of the MitraClip system in the treatment of patients
      with clinically significant mitral regurgitation with New York Heart Association (NYHA)
      Functional Class II to IV chronic heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the RESHAPE-HF1-FU Study is to follow up the safety and effectiveness of the
      MitraClip System in the treatment of clinically significant Functional Mitral Regurgitation
      (FMR) in patients with New York Heart Association (NYHA) Functional Class III or IV chronic
      heart failure, former participants in the RESHAPE-HF Trial (Abbott Vascular).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular (CV) death</measure>
    <time_frame>24 months</time_frame>
    <description>Composite rate of recurrent heart failure hospitalizations and cardiovascular (CV) death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation (MR) severity reduction</measure>
    <time_frame>at 12 and 24 months</time_frame>
    <description>Mitral Regurgitation (MR) severity reduction to mild or mild-to-moderate at 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minute Walk Test (6MWT)</measure>
    <time_frame>at 6, 12 and 24 months</time_frame>
    <description>Change in 6 Minute Walk Test (6MWT) distance at 6, 12 and 24 months over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV hospitalizations and CV death</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of recurrent CV hospitalizations and CV death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL)</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Quality of Life (QoL) overall score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ) at 12 months over baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Change in New York Heart Association (NYHA) Functional Class over baseline and proportions of patients in NYHA Functional Class I/II at 6, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Global Assessment (PGA)</measure>
    <time_frame>6, 12 and 24 months.</time_frame>
    <description>Change in Patient-reported Global Assessment (PGA) of well-being at 6, 12 and 24 months</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>standard care group</arm_group_label>
    <description>optimal standard of care therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>device group</arm_group_label>
    <description>Follow-up of MitraClip device implantation plus optimal standard of care therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The RESHAPE- HF1-FU Study is an observational, multi-center clinical evaluation (follow-up)
        of the MitraClip device plus optimal standard of care therapy (subjects with Device)
        compared to optimal standard of care therapy alone (other subjects), of former participants
        in the RESHAPE-HF Trial (Abbott Vascular).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Former participant in the RESHAPE-HF Trial (Abbott Vascular)

          -  Subject agrees to return for all required follow-up visits

          -  The subject has been informed of the nature of the study and agrees to the study's
             provisions and has provided written informed consent as approved by the respective
             clinical site's Ethics Committee

        Exclusion Criteria:

          -  Withdrawal of Informed Consent

          -  Subject belongs to a vulnerable population
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Anker, Prof.</last_name>
    <phone>(+)49 30 450 553 151</phone>
    <email>s.anker@cachexia.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolfgang Schillinger, Prof.</last_name>
    <phone>(+49)5551/97-12 44</phone>
    <email>schiwolf@med.uni-goettingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Schillinger, Prof.</last_name>
      <phone>(+49)551-39-6372</phone>
    </contact>
    <contact_backup>
      <last_name>Mark HÃ¼nlich, Dr.</last_name>
      <phone>(+49)551-39-6310</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph Stefan von Bardeleben, Dr.</last_name>
      <phone>(+49)6131-17-2892</phone>
    </contact>
    <contact_backup>
      <last_name>Tommaso Gori, Prof.</last_name>
      <phone>(+49)6131-17-2829</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

